These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 11841713)

  • 1. Carotid angioplasty and stent placement: a prospective analysis of perioperative complications and impact of intravenously administered abciximab.
    Qureshi AI; Suri MF; Ali Z; Kim SH; Lanzino G; Fessler RD; Ringer AJ; Guterman LR; Hopkins LN
    Neurosurgery; 2002 Mar; 50(3):466-73; discussion 473-5. PubMed ID: 11841713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abciximab as an adjunct to high-risk carotid or vertebrobasilar angioplasty: preliminary experience.
    Qureshi AI; Suri MF; Khan J; Fessler RD; Guterman LR; Hopkins LN
    Neurosurgery; 2000 Jun; 46(6):1316-24; discussion 1324-5. PubMed ID: 10834637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of high-dose intravenous eptifibatide as an adjunct to internal carotid artery angioplasty and stent placement: a prospective registry.
    Qureshi AI; Siddiqui AM; Hanel RA; Xavier AR; Kim SH; Kirmani JF; Boulos AS; Hopkins LN
    Neurosurgery; 2004 Feb; 54(2):307-16; discussion 316-7. PubMed ID: 14744276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracarotid abciximab injection to abort impending ischemic stroke during carotid angioplasty.
    Ho DS; Wang Y; Chui M; Wang Y; Ho SL; Cheung RT
    Cerebrovasc Dis; 2001; 11(4):300-4. PubMed ID: 11385208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abciximab reduces monocyte tissue factor in carotid angioplasty and stenting.
    Kopp CW; Steiner S; Nasel C; Seidinger D; Mlekusch I; Lang W; Bartok A; Ahmadi R; Minar E
    Stroke; 2003 Nov; 34(11):2560-7. PubMed ID: 14563968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial experience of platelet glycoprotein IIb/IIIa inhibition with abciximab during carotid stenting: a safe and effective adjunctive therapy.
    Kapadia SR; Bajzer CT; Ziada KM; Bhatt DL; Wazni OM; Silver MJ; Beven EG; Ouriel K; Yadav JS
    Stroke; 2001 Oct; 32(10):2328-32. PubMed ID: 11588321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intra-arterial reteplase and intravenous abciximab in patients with acute ischemic stroke: an open-label, dose-ranging, phase I study.
    Qureshi AI; Harris-Lane P; Kirmani JF; Janjua N; Divani AA; Mohammad YM; Suarez JI; Montgomery MO
    Neurosurgery; 2006 Oct; 59(4):789-96; discussion 796-7. PubMed ID: 16915119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Open-label phase I clinical study to assess the safety of intravenous eptifibatide in patients undergoing internal carotid artery angioplasty and stent placement.
    Qureshi AI; Ali Z; Suri MF; Kim SH; Fessler RD; Ringer AJ; Guterman LR; Hopkins LN
    Neurosurgery; 2001 May; 48(5):998-1004; discussion 1004-5. PubMed ID: 11334301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization.
    Ibbotson T; McGavin JK; Goa KL
    Am J Cardiovasc Drugs; 2003; 3(5):381-6. PubMed ID: 14728074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abciximab in carotid stenting for postsurgical carotid restenosis: intermediate results.
    Schneiderman J; Morag B; Gerniak A; Rimon U; Varon D; Seligsohn U; Shotan A; Adar R
    J Endovasc Ther; 2000 Aug; 7(4):263-72. PubMed ID: 10958289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.
    EPILOG Investigators
    N Engl J Med; 1997 Jun; 336(24):1689-96. PubMed ID: 9182212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication.
    Topol EJ; Ferguson JJ; Weisman HF; Tcheng JE; Ellis SG; Kleiman NS; Ivanhoe RJ; Wang AL; Miller DP; Anderson KM; Califf RM
    JAMA; 1997 Aug; 278(6):479-84. PubMed ID: 9256222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent.
    Cho L; Topol EJ; Balog C; Foody JM; Booth JE; Cabot C; Kleiman NS; Tcheng JE; Califf R; Lincoff AM
    J Am Coll Cardiol; 2000 Aug; 36(2):381-6. PubMed ID: 10933346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS.
    Lenderink T; Boersma E; Ruzyllo W; Widimsky P; Ohman EM; Armstrong PW; Wallentin L; Simoons ML;
    Am Heart J; 2004 May; 147(5):865-73. PubMed ID: 15131544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of glycoprotein IIb/IIIa inhibitors in carotid angioplasty and stenting.
    Wholey MH; Wholey MH; Eles G; Toursakissian B; Bailey S; Jarmolowski C; Tan WA
    J Endovasc Ther; 2003 Feb; 10(1):33-41. PubMed ID: 12751927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bleeding risks with abciximab after full-dose thrombolysis in rescue or urgent angioplasty for acute myocardial infarction.
    Jong P; Cohen EA; Batchelor W; Lazzam C; Kreatsoulas C; Natarajan MK; Strauss BH
    Am Heart J; 2001 Feb; 141(2):218-25. PubMed ID: 11174335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: insights from the very early outcomes in the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trial.
    Marmur JD; Mitre CA; Barnathan E; Cavusoglu E
    Am Heart J; 2006 Nov; 152(5):876-81. PubMed ID: 17070148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention.
    Suleiman M; Gruberg L; Hammerman H; Aronson D; Halabi M; Goldberg A; Grenadier E; Boulus M; Markiewicz W; Beyar R
    J Invasive Cardiol; 2003 Jun; 15(6):319-23. PubMed ID: 12777670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial.
    Moliterno DJ;
    Catheter Cardiovasc Interv; 2011 Jun; 77(7):1001-9. PubMed ID: 21598351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention.
    Akkerhuis KM; Deckers JW; Lincoff AM; Tcheng JE; Boersma E; Anderson K; Balog C; Califf RM; Topol EJ; Simoons ML
    JAMA; 2001 Jul; 286(1):78-82. PubMed ID: 11434830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.